Active substances
Mometasone + Olopatadine
- SFDA 3
- US FDA 1
- Health Canada 1
- US price lines 1
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RYALTRIS | 600,25 µg,µg | Nasal spray · Nasal use | 1 Bottle | SAR 73.50 | NCE · Prescription | Glenmark Specialty S A | Valid |
| RYALTRIS | 600,25 µg,µg | Nasal spray · Nasal use | 1 Bottle | SAR 36.75 | NCE · Prescription | Glenmark Specialty S A | Valid |
| RYALTRIS | 600,25 µg,µg | Nasal spray · Nasal use | 1 Bottle | SAR 17.15 | NCE · Prescription | Glenmark Specialty S A | Valid |
Indications — CHI Daman Drug Formulary
ALLERGIC RHINITIS; ALLERGIC RHINITIS-ALLERGIC RHINO-CONJUNCTIVITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| RYALTRIS | 0.025MG/SPRAY;0.665MG/SPRAY | spray, metered · nasal | GLENMARK SPECLT | Prescription | 13 Jan 2022 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| RYALTRIS | 02531186 | 665 MCG / ACT; 25 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | GLENMARK SPECIALTY SA |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | RYALTRIS 665-25 MCG SPRAY | $7.67149 | per GM | 23 Sep 2026 |
| NHS Drug Tariff | Mometasone 25micrograms/dose / Olopatadine 600micrograms/dose nasal spray | £13.32 | 240 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.